TY - JOUR T1 - Large-scale cross-sectional seroepidemiologic study of COVID-19 in Japan: Acquisition of herd immunity and the vaccines’ efficacy JF - medRxiv DO - 10.1101/2022.01.13.22269203 SP - 2022.01.13.22269203 AU - Zhenxiao Ren AU - Mitsuhiro Nishimura AU - Lidya Handayani Tjan AU - Koichi Furukawa AU - Yukiya Kurahashi AU - Silvia Sutandhio AU - Kaito Aoki AU - Natsumi Hasegawa AU - Jun Arii AU - Kenichi Uto AU - Keiji Matsui AU - Itsuko Sato AU - Jun Saegusa AU - Nonoka Godai AU - Kohei Takeshita AU - Masaki Yamamoto AU - Tatsuya Nagashima AU - Yasuko Mori Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/13/2022.01.13.22269203.abstract N2 - Background The COVID-19 pandemic situation has been changing drastically worldwide due to the continuous appearance of SARS-CoV-2 variants and the roll-out of mass vaccination. Periodic cross-sectional studies during the surge of COVID-19 cases is essential to elucidate the pandemic situation.Methods Sera of 1,000 individuals who underwent a health check-up in Hyogo Prefecture Health Promotion Association clinics in Japan were collected in August and December 2021. Antibodies against SARS-CoV-2 N and S antigens were detected in the sera by an electrochemiluminescence immunoassay (ECLIA) and an enzyme-linked immunosorbent assay (ELISA), respectively. The sera’s neutralization activities for the conventional SARS-CoV-2 (D614G), Delta, and Omicron variants were measured.Results The seropositive rates for the antibody against N antigen were 2.1% and 3.9% in August and December 2021 respectively, demonstrating a Delta variant endemic during that time; the actual infection rate was approximately twofold higher than the rate estimated based on the polymerase chain reaction (PCR)-based diagnosis. The anti-S seropositive rate was 38.7% in August and it reached 90.8% in December, in concordance with the vaccination rate in Japan. In the December cohort, 78.7% of the sera showed neutralizing activity against the Delta variant, whereas that against the Omicron was much lower at 36.6%.Conclusions These analyses revealed that herd immunity against SARS-CoV-2 including the Delta variant was established in December 2021, leading to convergence of the variants. The low neutralizing activity against the Omicron variant suggests the need for the further promotion of the prompt three-dose vaccination to overcome this variant’s imminent 6th wave in Japan.Summary Seroepidemiologic study of COVID-19 on December 2021 in Japan showed neutralizing antibodies for Delta were 78.7%, indicating the acquisition of herd immunity by mass vaccination leading to convergence while those for Omicron were only 36.6%, indicating need of booster vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Hyogo Prefectural Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The seroepidemiologic surveillance was approved by the Ethics Committee of Kobe University Graduate School of Medicine (approval code: B2156702). The Hyogo Prefecture Health Promotion Association was also granted approval for study participation under the same Ethics Committee. Information about this retrospective observational study was published on the website of Kobe University Hospital, along with the opportunity to opt out.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere is no available data referred to the manuscript. ER -